Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RaQualia Pharma (TSE:4579) Effective Interest Rate on Debt % Explanation
Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.
RaQualia Pharma Effective Interest Rate on Debt % Related Terms
RaQualia Pharma Effective Interest Rate on Debt % Historical Data
* Premium members only.
The historical data trend for RaQualia Pharma's Effective Interest Rate on Debt % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaQualia Pharma Effective Interest Rate on Debt % Chart
TSE:4579 vs VRTX, REGN, RVMD: Effective Interest Rate on Debt % Comparison
For the Biotechnology subindustry, RaQualia Pharma's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaQualia Pharma Effective Interest Rate on Debt % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RaQualia Pharma's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where RaQualia Pharma's Effective Interest Rate on Debt % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data,
the Interest Expense data used here is four times the quarterly (Mar. 2026) interest expense data.
Effective Interest Rate on Debt % is displayed in the 30-year financial page.
What does a Effective Interest Rate on Debt % of 2.13% mean?
RaQualia Pharma (TSE:4579) has a Effective Interest Rate on Debt % of 2.13% as of Mar. 2026. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on RaQualia Pharma and its competitors.
Is RaQualia Pharma's Effective Interest Rate on Debt % too high?
RaQualia Pharma's current Effective Interest Rate on Debt % is 2.13%. Overall, RaQualia Pharma has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Effective Interest Rate on Debt % compare to VRTX and REGN?
RaQualia Pharma's Effective Interest Rate on Debt % of 2.13% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Biotechnology company?
A good Effective Interest Rate on Debt % depends on the Biotechnology industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on RaQualia Pharma and its competitors. RaQualia Pharma's current Effective Interest Rate on Debt % is 2.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Overvalued. The stock's GF Value™ is 円311.01, compared to a current price of 円482.00 — trading 55% above its estimated fair value. The current Effective Interest Rate on Debt % is 2.13%. RaQualia Pharma's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Effective Interest Rate on Debt % is 2.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaQualia Pharma (TSE:4579) Overvalued in 2026?
Based on GuruFocus' analysis, RaQualia Pharma stock appears to be overvalued.
The current stock price of 円482.00 is trading 55% above its estimated GF Value™ of 円311.01.
GuruFocus considers RaQualia Pharma to be Significantly Overvalued.
Key valuation signals for TSE:4579:
Effective Interest Rate on Debt %: 2.13%
GF Value™: 円311.01 vs. price of 円482.00 (55% above fair value)
No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
60GF Score
Get the complete analysis for TSE:4579
Effective Interest Rate on Debt % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4579 has been successfully added to your 
